Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.73 |
| ▸ | NOS1 | P29475 | 3/20 | 0.73 |
| ▸ | NOS2 | P35228 | 3/20 | 0.73 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20502934 | 1.00 | NOS3 (0.73) | NOS3NOS1NOS2SLC7A5ALPI | |
| SCHEMBL20502933 | 1.00 | NOS3 (0.73) | NOS3NOS1NOS2SLC7A5ALPI | |
| SCHEMBL6046229 | 0.89 | NOS3 (0.71) | NOS3NOS1NOS2SLC7A5ALPI | |
| SCHEMBL3440766 | 0.88 | NOS3 (0.57) | NOS3NOS1NOS2NPSR1ALDH1A1 | |
| SCHEMBL22689784 | 0.87 | NOS3 (0.64) | NOS3NOS1NOS2SLC7A5ALPI | |
| SCHEMBL22689782 | 0.87 | NOS3 (0.64) | NOS3NOS1NOS2SLC7A5ALPI | |
| SCHEMBL29550135 | 0.87 | NOS3 (0.64) | NOS3NOS1NOS2SLC7A5ALPI | |
| SCHEMBL6776043 | 0.86 | NOS3 (0.67) | NOS3NOS1NOS2SLC7A5ALPI | |
| SCHEMBL2777855 | 0.86 | NOS3 (0.67) | NOS3NOS1NOS2SLC7A5ALPI | |
| SCHEMBL2777853 | 0.86 | NOS3 (0.67) | NOS3NOS1NOS2SLC7A5ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753719-B1 | SUBSTITUTED PYRROLIDINE-2-ONES | NOVARTIS AG (CH) | 2010-03-03 | — | — | EP | claimed |
| US-20070172421-A1 | Substituted pyrrolidine-2-ones | NOVARTIS AG (CH) | 2007-07-26 | — | — | US | claimed |
| CN-1960971-A | Substituted pyrrolidine-2-ones | NOVARTIS AG (CH) | 2007-05-09 | — | — | CN | claimed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-1753719-B1 | SUBSTITUTED PYRROLIDINE-2-ONES | NOVARTIS AG (CH) | 2010-03-03 | — | — | EP | disclosed |
| US-20070172421-A1 | Substituted pyrrolidine-2-ones | NOVARTIS AG (CH) | 2007-07-26 | — | — | US | disclosed |
| CN-1960971-A | Substituted pyrrolidine-2-ones | NOVARTIS AG (CH) | 2007-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | NOS3 4581/4885NOS1 4646/4885NOS2 4457/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | NOS3 4581/4885NOS1 4646/4885NOS2 4457/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | NOS3 4581/4885NOS1 4646/4885NOS2 4457/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | NOS3 4581/4885NOS1 4646/4885NOS2 4457/4885 |
| US-20070172421-A1 | Substituted pyrrolidine-2-ones | PRLHR, EPOR, FLT1 | NOS3 1187/4885NOS1 1052/4885NOS2 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.